Welcome to our dedicated page for Helix Acqsn II news (Ticker: HLXB), a resource for investors and traders seeking the latest updates and insights on Helix Acqsn II stock.
Helix Acquisition Corp II (HLXB) provides investors with critical updates through this dedicated news hub for this Special Purpose Acquisition Company. Access official press releases, merger disclosures, and regulatory filings in one centralized location designed for efficient tracking of corporate developments.
This resource delivers timely updates on HLXB's progress toward identifying and executing a business combination. Users will find essential documents including SEC filings, investor communications, and strategic announcements related to the SPAC's acquisition process.
The curated news collection focuses on three key areas: merger/acquisition status updates, leadership team communications, and financial structuring developments. All content is verified through primary sources to ensure compliance with financial disclosure regulations.
Bookmark this page for streamlined access to HLXB's evolving corporate narrative. Check regularly for updates during critical phases of the SPAC lifecycle, particularly as the company approaches its merger deadline.
Helix Acquisition Corp. II (NASDAQ:HLXB) has retained over 60% of its trust account after redemptions related to its business combination with BridgeBio Oncology Therapeutics (BBOT). The transaction is set to raise approximately $382 million in gross proceeds, comprising $120 million from Helix's trust account and $261 million from a PIPE financing.
The PIPE financing was led by Cormorant Asset Management and included notable investors such as ADAR1 Capital Management, Deerfield Management Company, and Wellington Management. This represents the 2nd lowest redemption rate for a biotech de-SPAC transaction since 2022. BBOT is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics for RAS and PI3Kα malignancies.
Helix Acquisition Corp. II (Nasdaq: HLXB) and BridgeBio Oncology Therapeutics (BBOT) announced that their registration statement for their proposed business combination has been declared effective by the SEC. The extraordinary general meeting of Helix shareholders is scheduled for August 4, 2025, with a record date of June 30, 2025.
BBOT is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics targeting RAS and PI3Kα malignancies. The company, originally a subsidiary of BridgeBio Pharma (Nasdaq: BBIO), focuses on improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. Upon closing, expected in August 2025, the combined company will be renamed "BridgeBio Oncology Therapeutics."
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II (HLXB) have announced a business combination agreement to create a publicly listed biotechnology company. The transaction, expected to complete in Q3 2025, will provide total proceeds of $450 million, combining HLXB's trust account funds and a $260 million PIPE financing led by Cormorant Asset Management.
The combined entity will focus on developing therapies for RAS and PI3Kα malignancies through three lead programs:
- BBO-8520: A KRASG12C inhibitor in Phase 1 trials for non-small cell lung cancer
- BBO-10203: An oral small molecule in Phase 1 trials for various cancers
- BBO-11818: A pan-KRAS inhibitor expected to begin patient dosing in H1 2025
The combined company is projected to have an implied pro forma equity value of $949 million at closing, assuming a $10.36 share price and no redemptions. BBOT shareholders will roll 100% of their equity into the combined company.
FAQ
What is the current stock price of Helix Acqsn II (HLXB)?
What is the market cap of Helix Acqsn II (HLXB)?
